Enlivex Therapeutics to Delist from TASE and Trade Exclusively on Nasdaq

Enlivex Therapeutics has initiated a process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange and focus exclusively on trading on the Nasdaq Capital Market. The last day of trading on the TASE is expected to be April 23, 2026, with delisting on April 26, 2026. The company's shares will continue to trade on Nasdaq under the symbol "ENLV." The decision aims to reduce administrative costs, enhance liquidity, and focus investor relations efforts on the U.S. capital markets.